Know Cancer

or
forgot password

Follow-up Observational Study of the Randomised Intergroup Trial of First Line Treatment for Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma With CHOP-Like Chemotherapy Regimen With or Without the Anti-CD20 Antibody Rituximab (IDEC-C2B8) [MINT]


N/A
18 Years
60 Years
Open (Enrolling)
Both
Long-term Effects Secondary to Cancer Therapy in Adults, Lymphoma

Thank you

Trial Information

Follow-up Observational Study of the Randomised Intergroup Trial of First Line Treatment for Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma With CHOP-Like Chemotherapy Regimen With or Without the Anti-CD20 Antibody Rituximab (IDEC-C2B8) [MINT]


OBJECTIVES:

- Gain information on the long-term efficacy of 6 courses of CHOP (cyclophosphamide,
doxorubicin hydrochloride, prednisone, and vincristine)-like chemotherapy with vs
without rituximab (plus involved-field radiotherapy to primary bulky disease) in young
patients with good-prognosis diffuse large B-cell non-Hodgkin's lymphoma treated on
protocol CAN-NCIC-LY9.

- Gain information on late toxicities, including secondary neoplasm occurring in young
good-prognosis patients treated on protocol CAN-NCIC-LY9.

OUTLINE: This is a multicenter study.

Patients successfully completing treatment on protocol CAN-NCIC-LY9 are followed every 3
months for 2 years, every 6 months for 3 years, and then annually thereafter.

PROJECTED ACCRUAL: A total of 667 patients will be accrued for this study.

Inclusion Criteria


DISEASE CHARACTERISTICS:

- Patients recruited for protocol CAN-NCIC-LY9 and evaluated in the first planned final
analysis as of June 2005

PATIENT CHARACTERISTICS:

- Not specified

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

Type of Study:

Observational

Study Design:

N/A

Outcome Measure:

Time to treatment failure

Principal Investigator

Michael G.M. Pfreundschuh, MD

Investigator Role:

Study Chair

Investigator Affiliation:

Universitaetsklinikum des Saarlandes

Authority:

United States: Federal Government

Study ID:

CDR0000514350

NCT ID:

NCT00400907

Start Date:

January 2006

Completion Date:

Related Keywords:

  • Long-term Effects Secondary to Cancer Therapy in Adults
  • Lymphoma
  • long-term effects secondary to cancer therapy in adults
  • stage I adult diffuse large cell lymphoma
  • contiguous stage II adult diffuse large cell lymphoma
  • noncontiguous stage II adult diffuse large cell lymphoma
  • stage III adult diffuse large cell lymphoma
  • stage IV adult diffuse large cell lymphoma
  • Lymphoma
  • Lymphoma, Non-Hodgkin
  • Lymphoma, B-Cell

Name

Location